Techonology and Science02 November, 20252 min read
Dilbert Creator Scott Adams Urges Trump to Force Kaiser to Deliver Life-Saving Cancer Drug Amid Rapid Decline
This article is an automated aggregation of coverage from news outlets. Our editorials offer in-depth analysis curated by the NewsCord team.
Scott Adams has metastasized prostate cancer and is rapidly declining. Kaiser Permanente approved Pluvicto, a new FDA-approved cancer drug, but treatment is delayed.
12 outlets told this the same way.
Scott Adams' Cancer Treatment Appeal
Scott Adams, the 68-year-old creator of Dilbert, says he is in rapid decline from metastatic prostate cancer.
“Pluvicto... is administered via a brief intravenous infusion that targets cancer cells expressing PSMA... Adams claims that Kaiser Permanente mishandled the scheduling of his Pluvicto treatment.”
He is urgently seeking Pluvicto, an FDA-approved IV radioligand therapy, after his provider Kaiser Permanente Northern California approved but then delayed scheduling his infusion.
He publicly appealed to former President Donald Trump for help.
Robert F. Kennedy Jr. also responded offering assistance.
Coverage varies in emphasis: Western mainstream outlets stress the health crisis and approval-versus-delay.
Western alternative outlets underscore the political intervention angle.
Asian coverage adds technical detail about Pluvicto’s mechanism and indication.
Political Response to Adams' Situation
Political and influencer intervention has accelerated the story’s visibility.
Daily Caller reports that Trump is 'on it' and that Dan Scavino said Trump, RFK Jr., and Dr. Oz were monitoring the situation.
The San Francisco Standard highlights the viral reach of Adams’ posts and support from figures like Bill Pulte, Pat Soon-Shiong, and Naval Ravikant.
The Post Millennial adds that Adams skipped his show to go to the ER and argued Trump is the only candidate who would 'bend the rules' to help.
Just the News gives a stripped-down account noting Adams plans to ask Trump for assistance after a prior offer to help.
Media Coverage of Adams' Diagnosis
Some outlets widen the political frame in different directions. Букви reports that Adams said he would contact President Joe Biden to intervene, even as it also notes Trump’s willingness to help and RFK Jr.’s support, and it invokes Trump’s Right to Try Act. Daily Mail similarly situates Adams’ diagnosis alongside Biden’s own prostate cancer announcement.
“Adams announced he would contact President Joe Biden to intervene... Former President Donald Trump responded publicly, expressing his willingness to help, with Health Secretary Robert F. Kennedy also offering support.”
By contrast, Fox News centers Trump’s potential role in expediting treatment. A singular report from World Tribune claims Adams is now scheduled for treatment on November 3, 2025 and had previously said his life expectancy was limited to summer 2025—details not found elsewhere and that sit uneasily with the sense of immediate urgency.
Media Perspectives on Adams
Media framing diverges on Adams’ public persona. Fox News notes reactions from commentators to Adams’ previously alleged racist remarks. Hindustan Times recaps his history of political predictions, some later listed among Politico’s 'worst predictions.'
The Post Millennial underscores his identity as a Trump supporter and includes his own provocative claim that Trump would 'bend the rules.' Daily Caller focuses on the details of the access dispute and rapid decline without highlighting past controversies.
Barriers to Accessing Treatment
Across outlets, the core access issue remains consistent: Adams says Kaiser Permanente Northern California approved Pluvicto but has not promptly scheduled the short IV infusion he believes could extend his life. Local and international sources frame this as emblematic of broader barriers to life‑saving drugs. The San Francisco Standard details insurance hurdles and outsized online attention.
“Adams claims that Kaiser Permanente mishandled the scheduling of his Pluvicto treatment.”
Букви underscores the challenge of accessing costly medicines. Hindustan Times and Daily Mail stress the scheduling mishap and Adams’ rapid decline. The throughline is Adams leveraging public pressure and political connections to accelerate care.
